Top

Osteoporosis International

Published in:

01-10-2007 | Original Article

Osteonecrosis of the jaw induced by orally administered bisphosphonates: incidence, clinical features, predisposing factors and treatment outcome

Authors: N. Yarom, R. Yahalom, Y. Shoshani, W. Hamed, E. Regev, S. Elad

Published in: Osteoporosis International | Issue 10/2007

Abstract

Summary

Osteonecrosis of the jaw (ONJ) is a well-known devastating side effect of bisphosphonate therapy for cancer. Several ONJ cases of patients using oral bisphosphonates have been reported in the literature. The present study analyzed the clinical features, predisposing factors, and treatment outcome of 11 patients with oral bisphosphonates-related ONJ.

Introduction and hypothesis

Osteonecrosis of the jaw (ONJ) is a well-known side effect of parenteral bisphosphonates therapy. Although ONJ has been reported in patients using oral bisphosphonates, documentation of this entity is sparse. It was hypothesized that the clinical features, predisposing factors, and treatment outcome of this population are different from those of oncologic patients.

Methods

This retrospective bi-central study involved 98 ONJ patients, 13 of whom were treated with oral bisphosphonates. Two patients were excluded because of previous use of intravenous bisphosphonates. The profiles of 11 patients were analyzed.

Results

The mean duration of alendronate use before developing ONJ was 4.1 years. ONJ was triggered by dental surgery in 9 patients and by ill-fitted dentures in 2. Heavy smokers were the most recalcitrant subjects. Among the nine patients with at least 6 months of follow-up, ONJ healed completely in three, partially in four, and not at all in two.

Conclusions

ONJ is a rare devastating side effect of oral bisphosphonates associated with patient morbidity and high financial burden. Clinicians must be aware of this entity and inform patients of the risks of dental surgery. The synergistic effect of smoking in the pathogenesis of ONJ should be further investigated.

Marx RE (2003) Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 61:1115–1117PubMedCrossRef

Wang J, Goodger NM, Pogrel MA (2003) Osteonecrosis of the jaws associated with cancer chemotherapy. J Oral Maxillofac Surg 61:1104–1107PubMedCrossRef

Marx RE, Sawatari Y, Fortin M, Broumand V (2005) Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 63:1567–1575PubMedCrossRef

Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL (2004) Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 62:527–534PubMedCrossRef

Farrugia MC, Summerlin DJ, Krowiak E, Huntley T, Freeman S, Borrowdale R, Tomich C (2006) Osteonecrosis of the mandible or maxilla associated with the use of new generation bisphosphonates. Laryngoscope 116:115–120PubMedCrossRef

Migliorati CA, Schubert MM, Peterson DE, Seneda LM (2005) Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy. Cancer 104:83–93PubMedCrossRef

Purcell PM, Boyd IW (2005) Bisphosphonates and osteonecrosis of the jaw. Med J Aust 182:417–418PubMed

Shlomi B, Levy Y, Kleinman S, Better H, Kahn A, Shtabsky A, Chaushu G (2005) Avascular necrosis of the jaw bone after bisphosphonate therapy. Harefuah 144:536–539, (in Hebrew)PubMed

Migliorati CA, Casiglia J, Epstein J, Jacobsen PL, Siegel MA, Woo SB (2005) Managing the care of patients with bisphosphonate-associated osteonecrosis: an American Academy of Oral Medicine position paper. J Am Dent Assoc 136:1658–1668PubMed

10.

Berenson JR, Lichtenstein A, Porter L, Dimopoulos MA, Bordoni R, George S, Lipton A, Keller A, Ballester O, Kovacs MJ, Blacklock HA, Bell R, Simeone J, Reitsma DJ, Heffernan M, Seaman J, Knight RD (1996) Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. N Engl J Med 334:488–493PubMedCrossRef

11.

Durie BG, Katz M, Crowley J (2005) Osteonecrosis of the jaw and bisphosphonates. N Engl J Med 353:99–102PubMedCrossRef

12.

Bamias A, Kastritis E, Bamia C, Moulopoulos LA, Melakopoulos I, Bozas G, Koutsoukou V, Gika D, Anagnostopoulos A, Papadimitriou C, Terpos E, Dimopoulos MA (2005) Osteonecrosis of the jaw in cancer after treatment with bisphosphonates:incidence and risk factors. J Clin Oncol 23:8580–8587PubMedCrossRef

13.

Hoff AO, Toth B, Altundag K, Guarneri V, Nooka A, Desrouleaux K, Klein M, Adamus A, Sayegh G, Worthing A, Gagel RF, Hortobagyi GN (2005) Osteonecrosis of the jaw in patients receiving intravenous bisphosphonate therapy. The 27th Annual Meeting of the American Society for Bone and Mineral Research; Abstract 1218

14.

Sambrook P, Cooper C (2006) Osteoporosis. Lancet 367:2010–2018PubMedCrossRef

15.

Cummings SR, Melton LJ (2002) Epidemiology and outcomes of osteoporotic fractures. Lancet 359:1761–1767PubMedCrossRef

16.

Cranney A, Guyatt G, Griffith L, Wells G, Tugwell P, Rosen C (2002) Summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev 23:570–578PubMedCrossRef

17.

Close P, Neuprez A, Reginster JY (2006) Developments in the pharmacotherapeutic management of osteoporosis. Expert Opin Pharmacother 7:1603–1615PubMedCrossRef

18.

American Dental Association Council on Scientific Affairs (2006) Dental management of patients receiving oral bisphosphonate therapy: Expert panel recommendations. J Am Dent Assoc 137:1144–1150

19.

Emkey RD Ettinger M (2006) Improving compliance and persistence with bisphosphonate therapy for osteoporosis. Am J Med 119:S18–S24PubMedCrossRef

20.

Solomon CG (2002) Bisphosphonates and osteoporosis. N Engl J Med 346:642PubMedCrossRef

21.

Hjorting-Hansen E (1970) Decortication in treatment of osteomyelitis of the mandible. Oral Surg Oral Med Oral Pathol 29:641–655PubMedCrossRef

22.

Baltensperger M, Gratz K, Bruder E, Lebeda R, Makek M, Eyrich G (2004) Is primary chronic osteomyelitis a uniform disease? Proposal of a classification based on a retrospective analysis of patients treated in the past 30 years. J Craniomaxillofac Surg 32:43–50PubMed

23.

Hansen T, Kunkel M, Weber A, James Kirkpatrick C (2006) Osteonecrosis of the jaws in patients treated with bisphosphonates - histomorphologic analysis in comparison with infected osteoradionecrosis. J Oral Pathol Med 35:155–160PubMedCrossRef

24.

Tada A, Senpuku H, Motozawa Y, Yoshihara A, Hanada N, Tanzawa H (2006) Association between commensal bacteria and opportunistic pathogens in the dental plaque of elderly individuals. Clin Microbiol Infect 12:776–781PubMed

25.

Levin L, Herzberg R, Dolev E, Schwartz-Arad D (2004) Smoking and complications of onlay bone grafts and sinus lift operations. Int J Oral Maxillofac Implants 19:369–373PubMed

26.

Schwartz-Arad D, Samet N, Samet N, Mamlider A (2002) Smoking and complications of endosseous dental implants. J Periodontol 73:153–157PubMedCrossRef

27.

Chapurlat RD, Delmas PD (2006) Drug insight: Bisphosphonates for postmenopausal osteoporosis. Nat Clin Pract Endocrinol Metab 2:211–219PubMedCrossRef

28.

Elad S, Yarom N, Hamed W, Ayalon S, Yahalom R, Regev E (2006) Osteomylelitis and necrosis of the jaw in patients treated with bisphosphonates. A comparative study. Clin Lab Haematol 28:393–398PubMedCrossRef

Title: Osteonecrosis of the jaw induced by orally administered bisphosphonates: incidence, clinical features, predisposing factors and treatment outcome
Authors: N. Yarom
R. Yahalom
Y. Shoshani
W. Hamed
E. Regev
S. Elad
Publication date: 01-10-2007
Publisher: Springer-Verlag
Published in: Osteoporosis International / Issue 10/2007
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI: https://doi.org/10.1007/s00198-007-0384-2

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Osteonecrosis of the jaw induced by orally administered bisphosphonates: incidence, clinical features, predisposing factors and treatment outcome

Abstract

Summary

Introduction and hypothesis

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Summary

Introduction and hypothesis

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 10/2007

Effect of low-intensity back exercise on quality of life and back extensor strength in patients with osteoporosis: a randomized controlled trial

Muscle mass deficits are associated with bone mineral density in men with idiopathic vertebral fracture

Corticosteroid-induced osteoporosis prevention: longitudinal practice patterns in The Netherlands 2001–2005

Adherence to treatment of osteoporosis: a need for study

Simple, novel physical activity maintains proximal femur bone mineral density, and improves muscle strength and balance in sedentary, postmenopausal Caucasian women

Standardised quantitative morphometry: a modified approach for quantitative identification of prevalent vertebral deformities